**Core Concept**
The patient's presentation is suggestive of a respiratory infection in a renal transplant patient, which necessitates consideration of opportunistic infections due to immunosuppression. The presence of clusters of cysts on bronchial brushings, staining with methenamine silver, is characteristic of Pneumocystis jirovecii pneumonia (PCP), a common opportunistic infection in immunocompromised patients.

**Why the Correct Answer is Right**
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment for PCP, an opportunistic infection caused by Pneumocystis jirovecii. TMP-SMX works by inhibiting dihydrofolate reductase, an enzyme essential for the synthesis of tetrahydrofolate, a precursor for DNA synthesis. This action disrupts the growth and replication of P. jirovecii, leading to resolution of symptoms. The use of TMP-SMX in this patient population is critical, as it not only treats the infection but also helps to prevent relapse and reduce mortality.

**Why Each Wrong Option is Incorrect**
**Option A:** Amphotericin B is an antifungal agent used to treat a variety of fungal infections, including aspergillosis and candidiasis. It is not the first-line treatment for PCP and may even exacerbate the condition due to its nephrotoxic effects, which could be detrimental in a renal transplant patient.

**Option B:** Cephalosporins are a class of antibiotics that are effective against a range of bacterial infections. However, they are not indicated for the treatment of PCP, as the causative agent is a fungus, not a bacterium.

**Option D:** Aminoglycosides are a class of antibiotics that are effective against certain bacterial infections, particularly those caused by gram-negative bacteria. However, they are not indicated for the treatment of PCP and may even be contraindicated in renal transplant patients due to their nephrotoxic effects.

**Clinical Pearl / High-Yield Fact**
In patients with PCP, a high level of suspicion should be maintained, even in the absence of characteristic symptoms or radiographic findings. TMP-SMX prophylaxis is recommended for all renal transplant patients, especially during the first 6-12 months post-transplant, to prevent PCP and reduce the risk of mortality.

**✓ Correct Answer: C. trimethoprim-sulfamethoxazole**